A Research Guide for
Cystic Fibrosis

Some babies have a positive newborn screen and one or two CFTR variants, but their sweat test and findings do not (yet) meet the definition of CF. This in-between situation is called CRMS in the U.S. (CFTR-Related Metabolic Syndrome) or CFSPID internationally.

Most children with CRMS/CFSPID stay healthy and never develop CF. A small number later meet criteria for CF or a CFTR-related disorder. Because of that uncertainty, these children are followed by a CF center over time. If your child has been given this label, ask the team what the monitoring plan is and what signs would prompt re-evaluation.

There are over 2,000 known CFTR variants. The most common is F508del. Variants are sometimes grouped by how they disrupt the protein (for example, the protein not being made at all, or being made but not working). What matters practically is this: your specific variants determine which modulator, if any, you are eligible for.

The 2026 U.S. label expansions broadened eligibility well beyond F508del — modulators are now approved for many variants that simply produce some CFTR protein. If you were told years ago that you "didn't qualify," it is worth asking again, because eligibility has changed.

A small percentage of people have variants that produce no CFTR protein at all (for example, certain "nonsense" or "stop" variants). Modulators do not work for these variants — which is why gene and mRNA therapies are being developed (see Advanced Therapy & Trials).

A CF "carrier" has one changed CFTR gene and one normal one. Carriers are healthy. CF only occurs when a child inherits a changed gene from both parents. If two carriers have a child, there is a 1-in-4 chance with each pregnancy that the child will have CF.

Carrier screening is widely available for people planning a family, and relatives of someone with CF may wish to be tested. Older carrier-screening panels checked only a limited set of variants and could miss carriers of non-European ancestry; ask for an expanded panel and consider genetic counseling.

• What did the sweat chloride test show, and what does that number mean?
• What are the exact CFTR variants, and based on those, what treatments are we eligible for?
• If this is a CRMS/CFSPID result, what is the monitoring plan and what would change it?
• Should other family members consider carrier testing or genetic counseling?
• For an adult newly diagnosed: which organs are already affected, and where do we start?

Alyftrek's appeal is convenience: one dose a day instead of two, which can make a real difference for adherence over a lifetime. In trials it performed at least as well as Trikafta. Switching is a reasonable conversation to have, but it is not automatic or urgent.

Points to discuss with your CF team: whether the once-daily schedule meaningfully helps you stick with treatment; how the two compare for your specific genotype and age; any differences in interactions with your other medicines; insurance coverage and cost; and a plan for monitoring (including liver blood tests) during and after a switch. Many people who are stable and doing well on Trikafta reasonably choose to stay on it. There is no single right answer — it is a personal decision made with your team.

People with CF are prone to specific lung bacteria, including Pseudomonas aeruginosa, Staphylococcus aureus (including MRSA), Burkholderia cepacia complex, and nontuberculous mycobacteria (NTM). When a new infection is caught early, the team may try to eradicate it; when it becomes chronic, the goal shifts to suppression.

Some CF bacteria can spread between people with CF. For this reason, CF clinics keep people with CF apart from one another, and the CF community avoids in-person gatherings of multiple people with CF. This "germ separation" can feel isolating, but it genuinely protects lung health. Good hand hygiene and prompt attention to new respiratory symptoms also matter.

An exacerbation is a flare-up of lung symptoms — more cough, more or thicker mucus, shortness of breath, tiredness, reduced appetite or weight, fever, or a drop in breathing test numbers. Exacerbations are treated with antibiotics (by mouth, inhaled, or intravenous depending on severity) and intensified airway clearance.

Red flags to call your CF team about: a clear, sustained increase in cough or mucus; coughing up blood; new or worsening shortness of breath; fever; or unexplained weight loss. Early treatment of exacerbations protects long-term lung function.

• Based on my genotype and age, am I eligible for Alyftrek, Trikafta, or another modulator?
• If I am on Trikafta, are there reasons to consider switching to once-daily Alyftrek — or to stay as I am?
• What monitoring do I need on a modulator (liver tests, eye exams), and how often?
• What is my current airway clearance routine, and is it still the right one now that I'm on a modulator?
• Do I have any chronic lung bacteria, and what is the plan for them?
• What enzyme dose and vitamins am I on, and should these be reviewed?
• Should I be doing anything differently with diet given the modulator?

Clinical trials are how new CF therapies are tested and how the field moves forward. Joining one is a personal decision with real considerations: trials may involve extra visits, procedures, and unknowns; some participants receive a placebo; and an experimental therapy may or may not help.

If you are interested, the CF Foundation maintains a clinical trials finder, and your CF center can tell you what is enrolling. Utah's CF centers participate in the national Therapeutics Development Network and run trials locally. Ask your team whether any current trial fits your genotype, age, and health status — and ask plainly about the time commitment, the risks, and what happens when the trial ends.

A transplant referral means your CF team connects you with a transplant center for evaluation. The evaluation assesses whether and when transplant might be appropriate. Many people are referred and evaluated long before they would actually need a transplant. Early referral gives you information, time to ask questions, and the ability to make decisions without crisis-level pressure. Utah has a lung transplant program at University of Utah Health; your CF team coordinates the referral.

• Given my genotype, am I someone for whom gene or mRNA therapy research is relevant?
• Are there any clinical trials I might be eligible for right now?
• What would joining a trial involve in terms of visits, procedures, and time?
• What is my current lung function, and how is it trending?
• Is it time to talk about a transplant referral — and if not now, what would trigger that conversation?

School and work accommodations. Children with CF may need time and a private space for treatments, enzymes with meals, extra bathroom access, and flexibility around medical appointments and illness. In the U.S., formal plans (such as a 504 plan) can put these in place. Adults may be entitled to reasonable workplace accommodations. CF centers and the CF Foundation can help you navigate this.

Exercise. Physical activity is genuinely beneficial in CF — for the lungs, bones, mood, and overall health. It should be encouraged, with attention to extra salt and hydration during heavy exercise or hot weather.

Building routines that last. CF treatment is a marathon. Routines that are realistic and built into the rhythm of the day are more sustainable than perfect routines that collapse under stress. It is okay to work with the team to simplify where the evidence allows.

Around the late teens, young people with CF move from a pediatric CF center to an adult CF program. A good transition is gradual and planned: the young person takes on more of their own care over time — ordering medications, attending parts of visits alone, knowing their genotype and medications — while still supported.

For families, this is an emotional shift as well as a logistical one. Start the conversation early with the pediatric team, and ask for a clear transition plan rather than an abrupt handoff.

Caregivers — parents, partners, and family — are central to CF care. This section is for you.

Daily airway clearance. For young children, airway clearance is something you do with them. Building it into a predictable rhythm (paired with a show, music, or a story) makes it sustainable. As children grow, gradually hand over ownership so the routine becomes theirs.

Medication and enzyme management. CF can involve many medicines: the modulator, enzymes with every meal and snack, vitamins, inhaled therapies, and more. A written schedule, pill organizers, phone reminders, and a "go bag" of enzymes for outings reduce the mental load. Keep an up-to-date medication list for every appointment and for emergencies.

Infection prevention. Hand hygiene, keeping nebulizer equipment clean and dry, staying current on vaccinations, and observing "germ separation" guidance all protect your child or family member. Ask the CF team for specific equipment-cleaning instructions.

School and work. Advocate early for accommodations — a plan in place before a problem arises is far easier than one negotiated in crisis. Give the school clear, simple written instructions about enzymes, treatments, and who to call.

Juggling multiple comorbidities. As a person with CF ages, care can expand to include diabetes, liver monitoring, bone health, and more — and more specialists. Ask the CF center to help coordinate so you are not managing a dozen disconnected appointments alone.

Emotional and financial support. CF carries real emotional and financial weight. The CF Foundation's Compass service offers free, personalized help with insurance, financial, and legal questions. CF social workers are part of the care team for exactly these issues. Use them.

Caregiver self-care — this is not optional. Caregiver burnout, anxiety, and depression are common and well-recognized. You cannot sustain care for someone else while running on empty. Accept help, protect some time for yourself, and treat your own mental health as part of the family's CF care. If you are struggling, tell the CF team — they expect this and can help.

• What screening am I due for — diabetes (glucose tolerance test), liver, bone density?
• Given that I'm on a modulator, is my weight and nutrition where it should be, or do we need to adjust?
• What support is available for anxiety, depression, or stress — for the patient and for caregivers?
• What accommodations should we put in place at school or work, and can you help?
• What is the plan for transitioning to adult care, and when should it start?
• For fertility or pregnancy questions: who should we talk to, and how far in advance?

Bring: an up-to-date list of all medicines and doses (including enzymes and vitamins); a note of any new symptoms and when they started; questions written down in advance; and, for children, the school plan if it needs updating.

Track between visits: respiratory symptoms (cough, mucus, breathlessness); weight and appetite; missed treatments and why; blood sugars if you have CFRD; and how you are doing emotionally.

During the visit: ask for current lung function numbers and how they compare to last time; confirm the plan in plain language; and ask who to contact, and how, between visits.

• A clear, sustained increase in cough or mucus, or a change in mucus color
• Coughing up blood
• New or worsening shortness of breath
• Fever, or feeling generally unwell with respiratory symptoms
• Unexplained weight loss or a marked drop in appetite
• Severe abdominal pain, persistent vomiting, or no bowel movements (possible bowel blockage)
• New excessive thirst, frequent urination, or unexplained fatigue (possible CFRD)
• New symptoms after starting or changing a modulator

For severe breathing difficulty, chest pain, or any emergency, seek emergency care immediately.

• If I travel or move abroad, how do I ensure continuity of my modulator supply?
• Are there international CF registries or organizations I should be connected with?
• If a family member lives in a country without newborn screening, should they be tested?

• United States: ETI (Trikafta) is FDA-approved for approximately 90% of eligible CF patients and is covered by most commercial insurance and Medicaid programs, with financial assistance through Vertex One for underinsured patients.
• European Union / UK: ETI (marketed as Kaftrio in EU) is EMA-approved and reimbursed in most EU member states and the UK (NICE approval). However, reimbursement timelines and access conditions varied significantly across EU countries, with some nations achieving access years after others. The CF Foundation of Europe tracked these gaps extensively.
• Australia and Canada: Both TGA (Australia) and Health Canada have approved ETI; reimbursement through public health systems has been achieved following negotiation with Vertex.
• Lower- and middle-income countries: The situation is dramatically different. Vertex has made limited access agreements for some countries, but in most lower- and middle-income countries, ETI is unavailable at any price. This means the majority of the world’s CF population (predominantly in Eastern Europe, the Middle East, and parts of Asia) remains on pre-modulator era standard of care.

Why this matters in the US: Even in the US, access disparities exist. Racial and ethnic minority CF patients, uninsured individuals, and those in under-resourced states or lacking a proximate CF care center have lower rates of modulator prescription and worse outcomes. The CF Foundation has launched equity initiatives targeting these access gaps, including mobile CF care programs and community health worker integration into CF care teams in underserved communities.

• CF Foundation (cff.org): US-based, operates the largest CF care center network, funds the majority of CF research, and provides patient services including CF Compass. Largest CF disease advocacy organization in the world.
• Cystic Fibrosis Europe (cfeurope.eu): Umbrella organization connecting national CF associations across Europe. Publishes the Brussels Declaration on access to care and the annual European CF Survey data.
• Cystic Fibrosis Canada (cysticfibrosis.ca): Canada’s national CF organization. Operates a patient registry and advocates for equitable provincial drug coverage.
• Cystic Fibrosis Australia (cfaustralia.org.au): Australia’s peak CF body; supported successful negotiation of PBS coverage for modulators.
• CF Medical Research Trust (UK, cfmrt.org.uk): UK-focused research funding body. Works alongside Cystic Fibrosis Trust (cysticfibrosis.org.uk) on patient services and advocacy.
• ECFS (European Cystic Fibrosis Society, ecfs.eu): Professional medical organization for CF clinicians and researchers across Europe. Publishes clinical trial and registry data through the ECFS Patient Registry.

• Staphylococcus aureus (MSSA): The most common early pathogen in CF, often found in infants and young children before Pseudomonas becomes established. MSSA is readily treatable with oral and IV antibiotics (anti-staphylococcal penicillins, cephalosporins, clindamycin, trimethoprim-sulfamethoxazole depending on sensitivities). Chronic MSSA colonization is generally associated with a milder disease course than Pseudomonas.
• Methicillin-resistant Staphylococcus aureus (MRSA): Community-acquired MRSA (USA300 strain) and healthcare-associated MRSA (typically USA100) are both found in CF airways. MRSA colonization is associated with more rapid FEV1 decline than MSSA in some registry studies. Oral options for MRSA are limited (TMP-SMX, linezolid, tedizolid); IV vancomycin or daptomycin is used for acute infections. The role of eradication therapy for MRSA in CF is less established than for Pa.
• Pseudomonas aeruginosa (Pa): The dominant pathogen in adult CF. Once chronic infection is established (typically defined as two or more positive cultures over 6 months or positive precipitating antibodies), Pa is virtually never eradicated. Chronic Pa infection drives progressive inflammatory lung damage. Mucoid Pa (producing alginate biofilm) is particularly resistant and is associated with accelerated decline. Management: cycled inhaled antipseudomonal antibiotics (tobramycin, aztreonam) plus azithromycin anti-inflammatory therapy and IV treatment for exacerbations.
• Burkholderia cepacia complex (Bcc): A group of closely related species (particularly B. cenocepacia and B. multivorans) that cause severe infections in CF. Bcc infections are associated with dramatically worse prognosis, accelerated lung function decline, and the "cepacia syndrome" — a rapidly fatal necrotizing pneumonia that occurs in some patients. Bcc strains are often resistant to all or nearly all antibiotics, making treatment extremely challenging. Many CF centers institute strict infection control measures (patient separation) to prevent Bcc cross-transmission. Patients with Bcc are treated by highly experienced CF centers; lung transplantation is complicated by Bcc (some centers will not transplant Bcc-positive patients; others do so with specific protocols).
• Stenotrophomonas maltophilia: Increasingly common in CF airways; often found alongside Pa. Intrinsically resistant to many beta-lactam antibiotics and aminoglycosides. Susceptible organisms are treated with TMP-SMX, minocycline, or ticarcillin-clavulanate. Clinical significance in CF is debated — it may be a marker of advanced disease and antibiotic pressure rather than an independent pathogen.
• Haemophilus influenzae and Moraxella catarrhalis: Common in pediatric CF; less so in adults. Readily treated with standard oral antibiotics. Often found concurrently with early MSSA infection.
• Non-tuberculous mycobacteria (NTM): M. abscessus and M. avium complex (MAC) are increasingly identified in CF airways, with prevalence rising as patients live longer and receive more antibiotics. NTM infections in CF are particularly challenging: M. abscessus is inherently resistant to most standard antibiotics. Treatment involves 6–12+ months of combination therapy (amikacin, imipenem, azithromycin, clofazimine, bedaquiline for M. abscessus), carries significant toxicity, and is often only partially successful. NTM lung disease in CF requires evaluation at a CF center experienced in NTM management (very few centers have this expertise).
• Aspergillus fumigatus and Allergic Bronchopulmonary Aspergillosis (ABPA): Aspergillus species are common in CF sputum cultures; most represent colonization rather than true infection. The exception is ABPA — an allergic hypersensitivity reaction to Aspergillus antigens in the airway — which causes mucus impaction, airway damage, and FEV1 decline if untreated. ABPA in CF is treated with systemic corticosteroids (to suppress the immune reaction) combined with antifungal therapy (itraconazole, voriconazole). Note that azole antifungals interact significantly with ETI — dose adjustment of ETI is required when azoles are prescribed.

When your sputum culture comes back, the laboratory typically reports "susceptible (S)," "intermediate (I)," or "resistant (R)" for each antibiotic tested. In CF, these standard sensitivity thresholds were developed for bloodstream infections and may not be clinically predictive for the airway — because inhaled antibiotics achieve concentrations 100-fold or more above the standard MIC breakpoints, organisms that test as "resistant" by standard criteria may still respond clinically to inhaled tobramycin or aztreonam. This is why CF physicians and CF clinical microbiologists interpret CF antibiotic sensitivities differently from standard infectious disease practice: in vitro resistance does not always mean in vivo failure in the inhaled antibiotic context. Discuss your culture results with your CF pulmonologist; don’t interpret them in isolation.

The CF Foundation defines a pulmonary exacerbation as meeting 4 or more of the following criteria (adapted from the Fuchs CFPE definition used in clinical trials):

• Change in sputum character (color, volume, consistency)
• New or increased hemoptysis
• Increased cough
• Increased dyspnea
• Malaise, fatigue, or lethargy
• Temperature above 38°C (100.4°F)
• Anorexia or weight loss
• Sinus pain or tenderness
• Change in sinus discharge
• Change in physical examination of chest
• Decrease in pulmonary function (FEV1 ≥10% below best recent value)
• Radiographic changes indicative of pulmonary infection

Not all of these are required. The clinician’s gestalt and the patient’s knowledge of their own baseline are equally important. Many experienced CF patients recognize an exacerbation before formal criteria are met and contact their care team immediately — this early contact is encouraged, as earlier treatment is associated with better recovery.

Exacerbation severity determines the treatment setting and antibiotic route:

• Mild-to-moderate exacerbations with Staphylococcus aureus (MSSA or MRSA), Haemophilus influenzae, or sensitive strains of other organisms are often treated with oral antibiotics (appropriate for the specific organism and sensitivities) in the outpatient setting. Oral fluoroquinolones (ciprofloxacin, levofloxacin) have anti-Pseudomonas activity but resistance develops rapidly with repeated use; they are generally reserved for situations where IV therapy is not feasible.
• Moderate-to-severe exacerbations, particularly in the context of chronic Pseudomonas infection, typically require intravenous antipseudomonal antibiotics (beta-lactams such as piperacillin-tazobactam, ceftazidime, meropenem or imipenem; plus an aminoglycoside such as tobramycin for combination synergy). IV antibiotics may be administered in hospital or via home IV services (OPAT: Outpatient Parenteral Antibiotic Therapy), allowing treatment at home for appropriate patients.
• Duration: Typically 14 days for a standard exacerbation. Longer courses (21+ days) may be used for severe exacerbations not responding to 14 days, guided by spirometry response and symptom resolution.

The goal of exacerbation treatment is return to pre-exacerbation lung function baseline. Discharge from the hospital or completion of an antibiotic course should be timed to lung function return, not just symptom resolution — spirometry should be checked before antibiotic course completion.

CFTR modulators fall into two mechanistic categories:

• Correctors (lumacaftor, tezacaftor, elexacaftor) address "processing" mutations like F508del, which produce a misfolded CFTR protein that is degraded before reaching the cell surface. Correctors help the misfolded protein fold correctly and traffic to the membrane.
• Potentiators (ivacaftor) address "gating" mutations like G551D, where CFTR reaches the membrane but doesn’t open its chloride channel properly. Ivacaftor keeps the channel open longer, increasing chloride transport.

The F508del mutation (present in approximately 85% of CF patients in at least one allele) has both a processing AND a gating defect — hence why triple combination therapy (two correctors + one potentiator) is needed for maximum effect on F508del CFTR. The HERALD and VX-445-101 trials that established ETI showed FEV1 improvements of 13–14 percentage points versus placebo in F508del homozygous patients — a magnitude of effect previously unimaginable with any CF therapy.

CFTR modulator eligibility depends on having at least one CFTR mutation that the specific drug can act on:

• ETI (Trikafta, US; Kaftrio, EU): FDA-approved for patients with at least one F508del allele (ages 2+), plus an expanded list of 177 additional non-F508del mutations. Approximately 90% of CF patients in the US are eligible. This expanded mutation list was determined using in vitro validated organoid and HBE cell assay data.
• Ivacaftor alone (Kalydeco): FDA-approved for 97 specific gating and residual-function mutations (ages 1 month+) not including F508del homozygous patients (though F508del heterozygous patients with one responding mutation are eligible).
• Tezacaftor/ivacaftor (Symdeko): Largely superseded by ETI for F508del patients; still used in some eligibility categories

Approximately 10% of CF patients have mutations where no currently approved modulator is active — primarily those with two severe stop or frameshift mutations that produce minimal or no CFTR protein (class I mutations). These patients face the original CF disease burden and are enrolled in trials of next-generation modulators, mRNA therapies, and gene editing approaches.

ETI is generally well tolerated. Key monitoring requirements and side effects:

• Liver function tests (LFTs): Transaminase elevations occur in 6–15% of patients on ETI, usually in the first 12 weeks. LFTs should be measured at baseline, at 3 and 12 months, and annually thereafter. If transaminases rise to >5x upper normal, ETI should be interrupted and hepatology involved.
• Eye examinations in pediatric patients: Non-congenital lens opacities were observed in pediatric patients in clinical trials. Baseline and periodic ophthalmologic monitoring is recommended in patients <13 years of age.
• Drug interactions: ETI is metabolized by CYP3A4. Strong CYP3A inducers (rifampin, carbamazepine, phenytoin, St. John’s Wort) dramatically reduce ETI plasma levels and should be avoided. Strong CYP3A inhibitors (azole antifungals: fluconazole, itraconazole, voriconazole; ciprofloxacin at high doses) increase ETI levels; dose adjustment of ETI is required with these combinations. This is particularly relevant because CF patients are frequently treated with azole antifungals for Aspergillus.
• Expected benefits: Most patients experience FEV1 improvements of 10–15 percentage points, dramatic reduction in pulmonary exacerbations (by approximately 60–70%), improved nutritional status, dramatic reduction in sweat chloride (often to below 60 mmol/L, near-normal range), improved sinus symptoms and anosmia, and — for many patients — the first sustained period of "feeling well" rather than "managing illness." Body weight often increases substantially in the first year. These benefits are maintained over years; long-term registry data through 5 years continue to show sustained improvement.

The Cystic Fibrosis Foundation (cff.org) operates the largest patient-support infrastructure in rare disease. Key programs:

• CF Foundation Compass: A free, 1-on-1 support service staffed by benefits specialists who help patients navigate insurance, financial assistance, social services, and mental health resources. Available by phone and online chat. This is the single most important resource for financial and benefits navigation in CF.
• CF Care Center Network: All CF Foundation-accredited care centers have patient care coordinators and social workers trained in insurance navigation and benefit optimization. They know local resources that CF Foundation Compass may not know.
• Vertex Patient Assistance programs: For Trikafta, Symdeko, Kalydeco, and Orkambi, Vertex has patient assistance programs (Vertex One at 1-877-752-5933) that provide the drugs free of charge to qualifying uninsured or underinsured patients and provides co-pay assistance for insured patients with commercial plans.

Prior authorization (PA) is required by most insurance plans before they will cover expensive CF medications. Common strategies for PA approvals and appeals:

• Ensure the PA documentation includes the patient’s CFTR genotype (which establishes eligibility for CFTR modulators), recent lung function data (FEV1), and physician attestation of medical necessity
• When a PA is denied, always request a peer-to-peer review: the CF pulmonologist speaks directly with the insurance plan’s medical director to explain clinical necessity. Peer-to-peer appeals overturn initial denials frequently
• External appeal: if internal appeals are exhausted, most states allow an independent external appeal by a third-party medical reviewer. External appeals overturn insurer denials in approximately 50% of cases for CF medications
• State insurance commissioner complaints: filing a complaint with your state’s insurance commissioner for unreasonable or protracted denials can accelerate resolution

Your CF care center’s social worker or patient care coordinator can assist with all of the above and should be your first call when insurance denies or delays a CF medication.

Inhaled tobramycin is the most established inhaled antibiotic in CF and the one with the longest evidence base. TOBI inhalation solution (tobramycin 300 mg twice daily) was approved in 1997 and demonstrated significant improvements in FEV1 and reduction in Pa density in pivotal trials. TOBI Podhaler (tobramycin 112 mg inhaled from a dry powder inhaler) was approved later as a more convenient administration option requiring no nebulizer. Both have equivalent clinical efficacy. Key management points:

• Use in 28 days on / 28 days off cycles
• Administer AFTER dornase alfa and before hypertonic saline in the daily medication sequence (typically: dornase alfa → airway clearance → hypertonic saline → inhaled antibiotics)
• Monitor for auditory changes: tobramycin has ototoxicity potential with systemic accumulation. Audiometry should be performed annually in patients on chronic inhaled tobramycin therapy
• Renal monitoring: systemic tobramycin absorption from inhaled route is low but should be considered in patients with impaired renal function
• Tobramycin resistance in Pa isolates can develop over time; culture and sensitivity results should guide continued use

Aztreonam lysine for inhalation (Cayston, 75 mg three times daily via eFlow nebulizer) was approved by the FDA in 2010 for CF patients with Pa infection. It is a beta-lactam antibiotic specifically formulated for inhalation. Its activity against Pa is complementary to tobramycin, and some patients cycle between the two drugs in alternating months to reduce the development of resistance. Clinical trials showed significant FEV1 improvement and reduction in Pa burden compared to placebo. Patients who have tobramycin-resistant Pa often respond to Cayston. The eFlow nebulizer required for Cayston is more efficient than standard nebulizers but is a proprietary device.

Azithromycin (oral macrolide): Not technically an inhaled antibiotic, but widely used as an anti-inflammatory and immunomodulatory agent in CF patients chronically infected with Pa. Three times weekly or daily dosing. The evidence for reduced exacerbation frequency and modest FEV1 benefit in Pa-positive CF patients is robust (multiple RCTs). Azithromycin is believed to work primarily through anti-inflammatory mechanisms rather than direct antibiotic killing of Pa (which is largely azithromycin-resistant). It is not recommended in Pa-negative patients based on current evidence. Monitor for QTc prolongation, particularly with other QT-prolonging drugs.

When Pseudomonas aeruginosa is first detected in a CF airway culture ("new acquisition"), prompt eradication therapy significantly delays establishment of chronic infection. The window for eradication is narrow — once chronic infection is established, eradication is rarely achievable. Standard eradication protocols include 28 days of inhaled tobramycin (with or without concurrent oral ciprofloxacin for 2–3 weeks). Multiple eradication attempts are reasonable; success rates for first-time Pa eradication with intensive therapy are approximately 70–90% in non-mucoid strains. Mucoid Pa (producing an alginate biofilm) is harder to eradicate and typically signals the transition to chronic infection. Successful eradication substantially impacts long-term prognosis; this is an urgent therapeutic priority when first Pa culture returns positive.

People with CF have a significantly higher rate of low bone density, osteopenia, and osteoporosis than the general population, driven by multiple overlapping mechanisms: fat-soluble vitamin D and K deficiency (impairs calcium absorption and bone mineralization), malnutrition, chronic systemic inflammation with elevated cytokines that activate osteoclasts, physical inactivity during exacerbations, glucocorticoid use, delayed puberty, and hypogonadism (particularly in males). DXA (dual-energy X-ray absorptiometry) bone density scanning is recommended starting at age 18 in patients with risk factors (or at 10 years in patients with severe disease). Fracture history, particularly vertebral fractures, is a sign of severe bone disease and requires aggressive management.

Treatment includes vitamin D and K supplementation (to target levels), calcium intake optimization, bisphosphonate therapy (alendronate, zoledronic acid, pamidronate) for significant osteoporosis — with caution in patients of reproductive age (bisphosphonates have a long bone half-life and potential fetal effects), and weight-bearing exercise. CFTR modulators — particularly ETI — have been shown to improve bone density in real-world data, likely through improved nutritional status and reduced systemic inflammation.

Virtually all adults with CF (nearly 100%) have chronic sinusitis on imaging, though symptoms vary widely. Like the lower airway, CF sinuses have impaired mucociliary clearance, accumulate thick mucus, and become colonized with the same bacteria (Pseudomonas, Staphylococcus, Stenotrophomonas). Chronic sinusitis in CF causes persistent nasal congestion, anosmia (loss of smell), headache, and post-nasal drip. The sinuses also serve as a reservoir from which bacteria can be aspirated into the lungs, particularly after sinus surgery or during exacerbations.

Management options include daily nasal saline irrigations (pulsed or squeeze-bottle sinus rinse with saline, sometimes with dissolved antibiotics such as tobramycin added for Pseudomonas), intranasal corticosteroid sprays, and endoscopic sinus surgery (ESS) when medical management fails. ESS for CF sinusitis requires an otolaryngologist (ENT) experienced in CF, because CF sinus anatomy is often abnormal. Importantly, CFTR modulators have dramatic effects on upper airway disease in many CF patients — some patients report resolution of chronic sinus symptoms and restoration of smell after starting ETI — an effect that is medically meaningful and often underappreciated by non-CF providers.

The standard US newborn screening algorithm for CF uses a two-step approach:

1. Immunoreactive trypsinogen (IRT): Elevated IRT in the heel-stick blood spot is the first-tier screen. IRT is a pancreatic enzyme precursor that leaks into the bloodstream when the CF pancreatic ducts are obstructed. All babies with CF and many CF carriers have elevated IRT at birth. However, IRT is also elevated by prematurity and other conditions, so a positive IRT requires follow-up.
2. DNA mutation analysis: If IRT is elevated, the same blood spot undergoes DNA testing for common CFTR mutations. Different states test for different numbers of mutations (anywhere from 23 to over 200 variants). If two mutations are found, the infant is referred for a diagnostic sweat chloride test. If one mutation is found and IRT is very high, the infant is also referred. If no mutations are found, the infant is usually discharged from screening follow-up (though very rare mutations could be missed).

Sweat chloride test: The definitive diagnostic test for CF. Pilocarpine is applied to the skin (typically the inner forearm) to stimulate sweat glands; sweat is collected and its chloride concentration measured. Chloride ≥60 mmol/L on two samples is diagnostic of CF. Chloride 30–59 mmol/L is intermediate (CFSPID — CF Screening Positive, Inconclusive Diagnosis) and requires further genetic analysis and follow-up. The sweat test should be performed at a CF Foundation-accredited care center with trained personnel to minimize errors in collection.

A positive newborn screen for CF creates enormous anxiety for families before the diagnosis is confirmed. Key points to share with families:

• Most infants with a positive IRT screen do NOT have CF — many are carriers or have other causes of elevated IRT. Confirmation requires the sweat chloride test.
• Even a confirmed CF diagnosis at birth does not mean the infant is currently sick. Most CF-positive infants are healthy at birth. The benefit of newborn screening is catching the condition before lung damage begins, not because the infant is ill now.
• The first CF center visit should happen within the first two weeks of life after a positive confirmatory sweat test. This visit establishes baseline lung and nutritional status, initiates PERT and vitamin supplementation, provides family education, and connects the family with the multidisciplinary CF team.
• Carrier implications: If one mutation is found and confirmed, parents of the child may want genetic counseling to understand their carrier status and implications for future pregnancies. If both parents are CF carriers, each future pregnancy has a 25% chance of CF.

For couples who know they are both CF carriers (each person carries one CFTR mutation), pre-conception or prenatal genetic testing is available:

• Preimplantation genetic testing (PGT-M): Used with IVF to test embryos for CF mutations before transfer, allowing selection of unaffected embryos. Offers the option of biological children without CF but involves IVF costs and complexity.
• Prenatal genetic testing: Chorionic villus sampling (CVS, typically performed 10–13 weeks) or amniocentesis (15–20 weeks) can test the fetus for CF mutations. These tests are highly accurate but carry small procedural risks.
• Carrier screening before planning: The American College of Obstetricians and Gynecologists (ACOG) recommends expanded carrier screening (including CF) for all people planning pregnancy. Knowing both partners’ carrier status before conception gives the most time to consider options including PGT-M.

Approximately 97–98% of males with CF are infertile due to congenital bilateral absence of the vas deferens (CBAVD). The vas deferens (the tube that carries sperm from the testes to the urethra) either fails to form or becomes obstructed during fetal development as a result of the same mucus abnormality that affects the lungs. This is not the same as impotence — sexual function, libido, and testosterone levels are typically normal. Sperm production continues in the testes. Sperm can be surgically retrieved from the testes (testicular sperm extraction, TESE) and used for in vitro fertilization with intracytoplasmic sperm injection (ICSI), which allows biological fatherhood. Pre-conception genetic counseling is strongly recommended: if a CF male partner with CBAVD plans biological parenthood with a female partner, the partner should be tested for CF carrier status first. If the partner is a CF carrier (1 in 25 in Caucasian populations), each pregnancy has a 50% chance of producing a child with CF.

Women with CF are generally fertile, though several factors can reduce fertility: abnormally thick cervical mucus (which can impair sperm penetration), irregular menstrual cycles during periods of poor nutritional status or exacerbation, and the nutritional and metabolic demands of pregnancy in the context of progressive lung disease. The key to successful pregnancy with CF is optimization of health status before conception — ideally FEV1 >50%, BMI within target range, stable CF management, and careful medication review (some CF medications are not safe in pregnancy). Since the introduction of CFTR modulators, more women with CF are pursuing pregnancy, and real-world registry data show generally good maternal and neonatal outcomes in well-managed patients on ETI. However, the evidence base on CFTR modulator safety in pregnancy is still developing, and the decision to continue or stop ETI during pregnancy should be made collaboratively with the CF care team and obstetric provider.

Most CF centers begin the transition process at age 16–18, with structured programs designed to build patient self-management skills before full transfer. The transition to adult care can feel abrupt: pediatric CF care is typically family-centered (parents often manage most of the treatment burden), while adult CF care is patient-centered and expects the patient to manage the daily regimen independently. Common challenges during transition include:

• Taking ownership of insurance management (often transitioning off parental plans at age 26)
• Navigating employment decisions and disclosing health status to employers
• Managing CF adherence alongside college demands, early careers, and new relationships
• Understanding fertility considerations and family planning timelines
• Assuming independent medical decision-making

Good adult CF centers run multidisciplinary teams (pulmonologist, physiotherapist, dietitian, social worker, psychologist, pharmacist) and typically see patients 3–4 times per year. The CF Foundation accredits adult CF care programs and their standards include minimum team composition requirements. Find your nearest accredited adult program at cff.org/care/care-center-network.

Lung transplantation is a life-extending but not curative treatment for CF. It replaces the diseased CF lungs with donor lungs that do not have the CF mutation — meaning the systemic manifestations of CF (sinusitis, CFRD, malabsorption) continue, but the pulmonary disease and respiratory failure are resolved. The current 5-year survival after lung transplant for CF is approximately 50–60% at experienced centers, which compares favorably with outcomes for other transplant indications but is significantly less than the long-term survival seen in younger patients on CFTR modulators.

Referral triggers (CF Foundation consensus):

• FEV1 declining to <40% predicted or rapid rate of FEV1 decline regardless of absolute value
• Six-minute walk distance <400 meters
• Increasing frequency of pulmonary exacerbations despite maximal therapy
• Hypoxemia at rest (SpO2 <88%) or rising carbon dioxide (hypercapnia)
• Massive hemoptysis or recurrent pneumothorax

Important note on modulators and transplant: CFTR modulators (particularly ETI) have significantly delayed — and in some patients may prevent — the need for transplant. However, patients who are already listed for transplant do not typically stop modulator therapy while waiting, and the modulator revolution has not made transplant evaluation irrelevant for the minority of patients who do not respond well to ETI or who have severe disease despite modulators. The interaction between modulator therapy and transplant waitlist management is an active area of clinical debate. Ask your CF pulmonologist at what FEV1 level they recommend initiating a transplant evaluation conversation.

The International Depression/Anxiety Epidemiological Study (TIDES) was a landmark cross-sectional study that systematically assessed mental health in CF across 154 CF centers in 6 countries. Key findings, published in the journal Thorax (2011), redefined how the CF community understands psychological comorbidity:

• Depression prevalence: 13% in CF adolescents, 19% in CF adults — 2–3 times the general population rate
• Anxiety prevalence: 22% in CF adolescents, 32% in CF adults — again, significantly higher than the general population
• Elevated depression and anxiety were associated with worse FEV1, worse BMI, more pulmonary exacerbations, and worse quality of life, even after controlling for disease severity — indicating that mental health independently worsens CF health outcomes, not just tracks them
• Despite high prevalence, fewer than 50% of those with TIDES-positive depression or anxiety were receiving any treatment — documenting a major treatment gap

As a direct result of TIDES, the CF Foundation and ECFS (European Cystic Fibrosis Society) jointly issued guidelines (2016, updated 2023) recommending annual mental health screening with validated tools for ALL CF patients aged 12 and above, at CF center visits:

• PHQ-9: For depression screening (score 0–27; ≥10 suggests moderate depression)
• GAD-7: For generalized anxiety disorder screening (score 0–21; ≥10 suggests moderate anxiety)
• If either screen is positive, referral to a CF-experienced mental health professional (psychologist or psychiatrist familiar with chronic illness) is recommended

Not all mental health treatments are equally appropriate in CF:

• SSRIs: Sertraline (Zoloft), escitalopram (Lexapro), and fluoxetine (Prozac) are generally considered safe first-line agents for depression in CF. QT-interval prolongation is a concern with some SSRIs (particularly citalopram and escitalopram at higher doses) in CF patients who may be taking other QT-prolonging antibiotics (azithromycin, fluoroquinolones). Baseline and on-treatment ECG monitoring is prudent in this context. Fluoxetine also inhibits CYP2D6 and may interact with some analgesics and other medications common in CF.
• SNRIs: Duloxetine (Cymbalta) and venlafaxine (Effexor) are also used in CF depression, particularly when there is a pain or fatigue component to the depression. Monitor for GI side effects, which are already common in CF.
• Benzodiazepines: use with extreme caution. While benzodiazepines (lorazepam, clonazepam, diazepam) can be appropriate for short-term acute anxiety or palliative care in CF, they should not be used as chronic anxiolytic therapy in CF patients with significant lung disease. Benzodiazepines cause central respiratory depression, reduce respiratory drive, and can precipitate respiratory failure in CF patients with elevated baseline CO2. They also suppress the cough reflex, impairing airway clearance. SSRIs/SNRIs, CBT, and buspirone are far preferable alternatives for chronic anxiety management.
• Cognitive Behavioral Therapy (CBT): The most evidence-based psychological intervention for depression and anxiety in chronic illness. Multiple small RCTs in CF specifically show that CBT improves depression and anxiety scores, adherence, and quality of life. Face-to-face CBT is highly effective; internet-delivered and telehealth CBT have expanded access significantly and are increasingly studied in CF populations. CF Foundation’s "CF Strong" program and ECFS’s "MATES" program are disease-specific CBT resources.
• Exercise as antidepressant: Regular aerobic exercise has antidepressant effects of comparable magnitude to SSRIs for mild-to-moderate depression in the general population. In CF, exercise has the added benefit of improving lung function and mucus clearance. Integrating exercise goals into CF mental health management is doubly beneficial.

Treatment fatigue — sometimes called CF "burnout" — refers to a syndrome of disengagement from the demanding daily treatment regimen after years or decades of compliance. It is distinct from clinical depression, though the two frequently co-occur. Key features:

• Studies show CF patients report average adherence of 40–60% to the full prescribed regimen, with airway clearance and exercise the least adhered-to components
• Burnout is most common in adolescents and young adults (ages 16–25), when peer normalization, independence-seeking, and denial are at their developmental peak
• Paradoxically, adherence sometimes temporarily improves with ETI because the visible/felt treatment benefit is motivating; some patients reduce adherence to other therapies after starting ETI on the belief that ETI "cures" CF, which requires careful counseling
• The CF Foundation’s SMARTT (Standardization of Measurement in Adherence Research and Treatment in CF) program and ECHO CF (Extension for Community Healthcare Outcomes) are initiatives supporting adherence and burnout management through quality improvement and telehealth

Strategies for managing treatment fatigue: shared decision-making about which regimen components are most important (working with the CF team to prioritize), scheduling treatments at fixed daily times to reduce decision burden, telehealth check-ins to maintain accountability without requiring clinic visits, peer support from other people with CF who have navigated the same challenges, and acknowledging the legitimacy of treatment fatigue without shame or blame.

• CF Foundation (cff.org/living-with-cf/mental-health): Mental health resources including the PEER Connect program (peer support from trained CF adults), mental health professional locator, and webinars on treatment adherence and burnout
• CF Trust (UK, cysticfibrosis.org.uk): "Climb" program — structured peer support specifically for people with CF managing mental health challenges; accessible internationally via online format
• CF Research Trust / Cystic Fibrosis Canada (cysticfibrosis.ca): Mental health and CF: a patient guide, available as downloadable PDF
• NACFC mental health workshops: The North American CF Conference (NACFC) routinely presents research and clinical sessions on CF mental health — conference recordings often available via CF Foundation membership
• Online peer support: Reddit r/CysticFibrosis, CysticLife (cysticlife.org), and Inspire.com CF forums provide peer perspective and community, particularly valuable for mental health topics where community understanding differs from clinical perspectives

As lung function declines, CF patients can maintain adequate oxygen saturation during the day (sitting upright, awake, with normal respiratory muscle tone) but experience significant oxygen desaturation during sleep — particularly during REM sleep, when normal suppression of accessory respiratory muscle tone is most pronounced. Key points:

• Nocturnal hypoxemia is defined as oxygen saturation (SpO2) <88% for ≥5 consecutive minutes or <90% for ≥10% of total sleep time during overnight polysomnography or oximetry
• Nocturnal hypoxemia contributes to pulmonary hypertension, right heart strain, erythrocytosis, and impaired neurological function
• Standard screening recommendation: overnight pulse oximetry for CF patients with FEV1 <65% predicted, or any patient with symptoms suggesting nocturnal desaturation (morning headaches, excessive daytime sleepiness, waking with dyspnea)
• Treatment: supplemental nocturnal oxygen for documented hypoxemia; non-invasive ventilation (BiPAP) for patients with hypercapnia (elevated CO2) or those who cannot maintain adequate saturation on oxygen alone. ETI may improve nocturnal hypoxemia by improving lung function and reducing mucus burden.
• Obstructive sleep apnea (OSA): CF patients, despite often having normal body habitus, can develop OSA due to nasal polyps, sinus disease, and increased upper airway resistance. Nasal CPAP or BiPAP is the treatment. Untreated OSA worsens nocturnal hypoxemia and sleep fragmentation.

• Complete airway clearance sessions 2–3 hours before bedtime so that secretion burden is minimized when supine
• Elevate the head of the bed (6–8 inches) to reduce both GERD aspiration risk and nocturnal secretion pooling in the posterior airways
• Take proton pump inhibitors (if prescribed for GERD) 30–60 minutes before the last meal of the day for optimal acid suppression during sleep; avoid large meals within 2 hours of bedtime
• If you take azithromycin, be aware it can prolong the QT interval — discuss with your CF physician if you also use any other QT-prolonging agents (certain antihistamines, antidepressants) and have any cardiac history
• Melatonin (0.5–5 mg at bedtime) may help with sleep onset for CF patients with circadian disruption from frequent hospitalizations, without the airway-drying effects of antihistamine sleep aids (which worsen mucus viscosity)

CF-related liver disease (CFLD) affects approximately 30% of CF patients and is the third leading cause of death in CF (after pulmonary disease and transplant complications). CFLD develops because CFTR dysfunction in the biliary epithelium leads to thick, inspissated bile that obstructs bile ducts, causing progressive inflammation and fibrosis. Key aspects:

• Screening: Annual liver function tests (ALT, AST, GGT), ultrasound every 1–2 years, and assessment for splenomegaly (a sign of portal hypertension) are standard. Transient elastography (FibroScan) provides non-invasive liver stiffness measurement to track fibrosis progression.
• Ursodeoxycholic acid (UDCA): UDCA improves bile flow and reduces biliary inflammation. It is widely used in CFLD despite limited RCT evidence of improved clinical outcomes; it is safe and biochemically beneficial. Dosing: 20 mg/kg/day divided in two doses. Approximately 50% of patients show biochemical improvement.
• Portal hypertension complications: Advanced CFLD can progress to cirrhosis and portal hypertension, causing esophageal varices (risk of life-threatening bleeding), hypersplenism (low platelets), and ascites. Patients with cirrhosis require annual upper endoscopy to screen for esophageal varices and beta-blocker prophylaxis if large varices are found. Transjugular intrahepatic portosystemic shunt (TIPS) or liver transplantation are interventional options for severe portal hypertension in eligible patients.
• ETI and liver disease: ETI appears to reduce liver disease progression in some patients — improved CFTR function in bile ducts reduces biliary inspissation. However, ETI is processed by the liver via CYP3A4; patients with advanced CFLD may have altered ETI metabolism, requiring dose adjustment. LFT monitoring every 3 months for the first year on ETI is recommended by the CF Foundation.
• GI complications: Beyond liver disease, CF causes pancreatic exocrine insufficiency (requiring PERT), GERD (very common; treat aggressively because aspiration of stomach acid worsens pulmonary disease), and distal intestinal obstruction syndrome (DIOS) — a partial or complete large bowel obstruction from inspissated intestinal contents at the ileocecal junction. DIOS presents as right lower quadrant pain and constipation; treatment is with oral N-acetylcysteine, Gastrografin enema, or polyethylene glycol (GoLYTELY/Miralax). DIOS is distinct from constipation but can be confused with it; inadequate PERT dosing is a major risk factor.

• Airway clearance: Increased respiratory rate and tidal volume during exercise promotes mucus mobilization. Exercise is often used as an adjunct to (not replacement for) formal ACT; patients often cough up significant secretions during aerobic exercise. Vigorous exercise 30 minutes before a formal ACT session can enhance mucus clearance efficacy.
• Exacerbation frequency: Registry data from the CF Foundation consistently show that physically fitter CF patients have fewer pulmonary exacerbations per year, independently of lung function. Fitness modifies exacerbation risk.
• FEV1 preservation: Long-term aerobic fitness is associated with slower FEV1 decline in CF. The mechanism is multifactorial: less mucus stasis, fewer exacerbations, and stronger respiratory musculature all contribute.
• Bone health: Weight-bearing exercise (walking, running, resistance training) stimulates bone formation and is important for preventing CF-related osteoporosis, particularly in patients who have required frequent corticosteroid courses.
• Mental health: Multiple CF studies show that regular exercise improves depression and anxiety scores, quality of life, and self-efficacy in CF. The social component of group exercise programs adds additional psychological benefit.

• General recommendation: 150 minutes of moderate-intensity aerobic exercise per week (same as general population guidelines), with additional resistance training 2–3 times/week for muscle strength and bone density
• Swimming: Particularly beneficial for CF because the warm humid air reduces bronchospasm, the horizontal position aids mucus drainage, and the full-body aerobic workout is excellent for cardiorespiratory fitness. Pools should be well-maintained; concern about Pseudomonas in poorly-maintained pools exists but should not preclude swimming in appropriate venues.
• Exercise-induced bronchospasm: Some CF patients (particularly those without ETI benefit) develop bronchospasm with exercise. Pre-exercise bronchodilator (albuterol 2 puffs 15–20 minutes before exercise) is standard in these cases. A post-exercise peak flow measurement can help assess response.
• Sodium and hydration: CF patients lose much more sodium in sweat than non-CF individuals. During intense exercise or in hot weather, additional salt replacement (1–2 g NaCl tablets or sports drinks) is required to prevent hyponatremic dehydration, which can be severe in CF. Patients often require 2–3x the usual sodium intake during heavy exercise in heat.
• CFRD and exercise: CF patients with CFRD must monitor blood glucose closely around exercise. Vigorous exercise can cause hypoglycemia; ensure glucose is not too low before exercising and have a rapid-acting glucose source available.
• Pulmonary rehabilitation programs: Formal CF pulmonary rehabilitation programs, where available, provide supervised aerobic training, individualized exercise prescription, breathing exercises, and psychosocial support. They are particularly valuable during post-exacerbation recovery when reconditioning is needed.

CFRD is not simply "having diabetes on top of CF." It has unique consequences for the overall CF disease state:

• Nutritional deterioration: Because insulin promotes protein anabolism (muscle synthesis) and its absence causes a catabolic state, CFRD leads to weight loss, muscle wasting, and nutritional decline in the period before diagnosis. Many patients with CFRD experience a 1–3 year period of unexplained weight loss or failure to gain weight before the diabetes is formally diagnosed — a period during which lung function often declines significantly. Early diagnosis and insulin treatment reverses this trajectory.
• Lung function decline: CFRD is independently associated with more rapid FEV1 decline and higher rates of pulmonary exacerbation, likely due to both the hyperglycemic airway environment (which promotes Pa growth) and the catabolic effects of insulin deficiency on respiratory muscle strength.
• Increased mortality: Before CFTR modulator therapy, CFRD was associated with significantly higher mortality in CF, particularly in females. With ETI, the relationships are being re-evaluated — ETI improves insulin secretion and may delay or reduce CFRD progression in some patients, though it does not reverse established CFRD.

CFRD often develops asymptomatically. The Cystic Fibrosis Foundation recommends annual oral glucose tolerance testing (OGTT) for all CF patients beginning at age 10, because fasting blood glucose and HbA1c are insensitive for early CFRD detection. The OGTT involves drinking a 75 g glucose solution, followed by a 2-hour blood glucose measurement:

• Normal: 2-hour glucose <140 mg/dL
• Indeterminate glycemia: 2-hour glucose 140–199 mg/dL (risk category, requires closer monitoring)
• CFRD: 2-hour glucose ≥200 mg/dL OR random glucose ≥200 mg/dL with symptoms, OR fasting glucose ≥126 mg/dL on two occasions

Note: HbA1c may underestimate glucose levels in CF due to accelerated red blood cell turnover; it is used for monitoring once CFRD is established but is less reliable as a diagnostic tool.

Continuous glucose monitoring (CGM) is increasingly used in CF centers to detect postprandial glucose spikes that the OGTT may miss, and to monitor glucose control in diagnosed CFRD. Many CF patients who have "normal" fasting glucose have significant postprandial hyperglycemia that may be driving early nutritional and pulmonary deterioration.

Insulin is the only evidence-based pharmacological treatment for CFRD. Unlike Type 2 diabetes, oral antidiabetic drugs (metformin, GLP-1 agonists, SGLT2 inhibitors) are not recommended as primary therapy in CFRD because CFRD is primarily an insulin-deficiency state, not an insulin-resistance state. The goals of CFRD treatment are somewhat different from standard diabetes management:

• Primary goal: Reversing the catabolic state and supporting weight gain/maintenance, not just glucose lowering
• Rapid-acting insulin with meals: Matching insulin to high-calorie CF meals; doses are often higher than for Type 1 diabetes of equivalent size because CF patients must eat more than typical diabetic patients to maintain weight
• Basal insulin (long-acting): Used when fasting glucose is also elevated or when meal bolus alone is insufficient
• HbA1c target in CFRD: Guidelines suggest <7% when achievable without hypoglycemia, but given that HbA1c underestimates true glucose in CF, management is often guided more by CGM time-in-range targets and weight/nutritional status
• Hypoglycemia awareness: CF patients often exercise intensively and have unpredictable caloric intake due to anorexia during exacerbations; hypoglycemia management education is important
• ETI and insulin needs: Many CFRD patients who start ETI find their insulin requirements decrease, and some experience spontaneous resolution of CFRD if it was in an early stage. However, stopping insulin without endocrinology guidance is not recommended.

CFRD is the most common non-pulmonary comorbidity in CF, affecting approximately 20% of adolescents and 40–50% of adults. It is caused by progressive destruction of insulin-secreting pancreatic beta cells (the same pancreatic damage that causes exocrine insufficiency) combined with insulin resistance during pulmonary exacerbations and use of corticosteroids. CFRD is distinct from both Type 1 and Type 2 diabetes:

• Unlike Type 1, it does not involve autoimmune beta-cell destruction
• Unlike Type 2, insulin secretion is severely impaired (not just resistance)
• The main metabolic priority is avoiding undernutrition — the high-calorie, high-fat CF diet means glucose management must be balanced carefully against the critical need to maintain weight
• Ketoacidosis is rare (some residual insulin secretion usually persists)
• Microvascular complications (retinopathy, nephropathy, neuropathy) do occur with prolonged poor glycemic control

Screening: Annual oral glucose tolerance test (OGTT) is recommended starting at age 10, as fasting glucose and HbA1c are not reliable for CFRD detection (OGTT detects early post-meal hyperglycemia that HbA1c misses because CF patients have high red blood cell turnover). Continuous glucose monitors (CGM) are increasingly used for both diagnosis and management.

Treatment: Insulin is the cornerstone of CFRD management. Insulin sensitizers used for Type 2 diabetes (metformin, GLP-1 agonists) are not recommended as primary agents in CFRD because weight loss and GI side effects worsen the nutritional challenges already inherent in CF. CFTR modulators — particularly ETI/Trikafta — have had a significant favorable impact on CFRD in many patients, with some patients showing reversal of pre-diabetic glucose tolerance after starting ETI.

CF liver disease affects approximately 30–40% of CF patients to some degree, though significant liver disease (cirrhosis, portal hypertension) develops in only 5–10%. It results from viscous bile obstructing intrahepatic bile ducts, leading to focal biliary cirrhosis over time. Risk factors include male sex, pancreatic insufficiency, and certain CFTR genotypes. CFLD is largely a silent condition until advanced: most patients have only mild transaminase elevations and do not develop cirrhosis.

Surveillance includes annual liver function tests, abdominal ultrasound (every 2–3 years), and platelet count (thrombocytopenia suggests developing portal hypertension). Ursodeoxycholic acid (UDCA, ursodiol) is widely used at doses of 15–20 mg/kg/day to improve bile flow and composition. Evidence for its clinical benefit is mixed — it clearly improves liver enzyme levels, but large randomized trials have not yet demonstrated that it prevents cirrhosis progression, and some studies raised concerns about high-dose UDCA. CF Foundation guidelines consider its use reasonable based on safety profile and biochemical benefit despite the uncertain long-term outcome data.

For patients who develop significant portal hypertension (varices, ascites), hepatology co-management becomes essential. Liver transplantation is performed at select centers for end-stage CFLD, and combined liver-lung transplantation has been performed at centers with combined programs. Again, ETI has shown favorable effects on liver function markers in real-world data, though long-term effects on CFLD progression are still being studied.

Contributing factors include the burden of daily treatments (ACT, nebulizers, PERT, vitamins, antibiotics), frequent hospitalizations, uncertainty about disease progression and transplant timing, social isolation during infections, fertility concerns, and the progressive physical changes that come with advancing disease. The CF Foundation and European CF Society now recommend annual mental health screening using validated tools (PHQ-9 for depression, GAD-7 for anxiety) at all accredited CF care centers. This is part of the TIDES-recommended CF Mental Health Consensus Guidelines.

Evidence-based interventions that have shown benefit in CF specifically include cognitive behavioral therapy (CBT) adapted for chronic illness, mindfulness-based stress reduction (MBSR), and peer support programs. The CFTR modulator revolution has also had measurable mental health benefits for many patients — reduced treatment burden, improved exercise tolerance, and the psychological relief of having a highly effective disease-modifying therapy all contribute to improved wellbeing scores in real-world data following ETI initiation.

Resources: The CF Foundation (cff.org) maintains a mental health resource page with clinician locator tools. The Cystic Fibrosis Psychosocial Working Group has published clinician guidelines for mental health integration into CF care. Ask your CF care team to include a psychologist or social worker as part of your annual comprehensive care visit if one is not already involved.

Approximately 85–90% of people with CF have exocrine pancreatic insufficiency, meaning they do not produce enough digestive enzymes (lipase, protease, amylase) to absorb fats and proteins normally. Without treatment, fat malabsorption causes fatty, foul-smelling stools (steatorrhea), weight loss, fat-soluble vitamin deficiency, and failure to thrive. Pancreatic enzyme replacement therapy (PERT) — encapsulated, enteric-coated microspheres of porcine pancreatic enzymes (Creon, Zenpep, Pancreaze) — must be taken with every meal and fat-containing snack.

Dosing: Starting doses for adults are typically 500–2,500 lipase units per kg of body weight per meal, with snacks at half the meal dose. The maximum recommended dose is 2,500 units/kg/meal or 10,000 units/kg/day to minimize the rare risk of fibrosing colonopathy from excessive PERT. Doses are adjusted based on stool characteristics and growth. Capsules should not be crushed; the enteric coating protects enzymes from stomach acid.

Signs of insufficient dosing: loose, greasy, or very frequent stools; abdominal cramping or bloating; difficulty maintaining weight despite good caloric intake.

Because CF-related fat malabsorption impairs absorption of fat-soluble vitamins, routine supplementation is standard care for all pancreatic-insufficient patients:

• Vitamin D: Deficiency is nearly universal without supplementation. Target 25-OH vitamin D level: 30–60 ng/mL. Many CF patients require 800–2,000 IU daily or more, with monitoring every 6–12 months. Low vitamin D is associated with reduced bone density and increased infection susceptibility.
• Vitamin A: Important for lung epithelial integrity and immune function. CF-specific multivitamins (ADEK vitamins, SourceCF) provide standardized doses. Routine monitoring is recommended to avoid toxicity.
• Vitamin E: An antioxidant that may help mitigate CF-related oxidative stress. Supplemented in all PI patients.
• Vitamin K: Required for blood clotting factors and bone metabolism. Patients on long-term antibiotics that deplete gut flora are at higher risk of K deficiency.

CF Foundation guidelines recommend CF-specific multivitamin formulations rather than standard adult multivitamins, which typically contain inadequate vitamin D and E doses for CF patients.

Standard CF dietary advice is the opposite of general population guidance: more fat, more calories, more salt. CF dietitians help design individualized plans, but general strategies include:

• Adding calorie-dense fats (butter, olive oil, avocado, nut butters, full-fat dairy) to every meal
• High-calorie oral supplements between meals when food alone is insufficient (Boost, Ensure, or CF-specific formulas)
• Salt replacement: CF sweat contains 3–5x more salt than average, so additional dietary sodium — especially during hot weather or exercise — prevents electrolyte imbalances
• For patients who cannot meet caloric needs orally, nasogastric (NG) or gastrostomy (G-tube) overnight supplemental feeds are effective for weight restoration. Many adolescents and adults use overnight G-tube feeds to supplement daytime oral intake without disrupting daily activities

Since the introduction of highly effective modulators (ETI/Trikafta), many patients have experienced dramatic improvements in appetite and nutritional status as lung disease burden decreases. Some patients have had to consciously moderate caloric intake as metabolic demand drops. Your dietitian is the right person to recalibrate targets as your health evolves.

PEP devices (Acapella, Flutter, Aerobika, RC-Cornet, Quake) generate resistance during exhalation, creating back-pressure that splints airways open and allows air to get behind mucus plugs. The oscillating variants (oscillating-PEP or OPEP) add vibration to the airflow, further loosening secretions. PEP techniques are widely used across age groups and do not require a second person to administer, making them highly practical for independent use at home, at school, or while traveling. Studies in adults with CF show PEP equivalent to other ACTs for FEV1 preservation over time. Flutter devices were among the earliest OPEP devices; Aerobika (Trudell Medical) and Acapella (Smiths Medical) are currently among the most prescribed in the US. Insurance typically covers these devices with a CF diagnosis code.

Questions to ask your care team: Which PEP device is right for my lung function level? How many cycles per session? Should I use it before or after inhaled antibiotics or dornase alfa?

The HFCWO vest (AffloVest, SmartVest, Vest Airway Clearance System by Hill-Rom) wraps around the chest and delivers rapid air pulses that gently shake the chest wall at 6–25 Hz. This frequency range is thought to optimize mucus rheology and stimulate cough. The vest allows truly hands-free therapy — patients can read, watch TV, or use a tablet during a 20–30 minute session. This independence is particularly valuable for adults, adolescents, and children old enough to use the device without direct parental assistance. Vest therapy is especially popular in the US and well-covered by most insurance when medically necessary documentation is provided. Both AC power and battery-operated models exist (AffloVest, SmartVest). The main limitation is cost (insurance negotiated price typically $15,000–$25,000) and the bulkiness of the device for travel.

ACBT is a structured sequence of breathing exercises performed in three phases: breathing control (gentle, relaxed tidal breathing), thoracic expansion exercises (slow, deep breaths with a 3-second inspiratory hold), and the forced expiration technique or "huff" (a moderately forceful exhalation from mid-to-low lung volumes, not a full cough). The cycle is repeated 3–4 times per session, typically 15–20 minutes. ACBT requires no equipment and can be self-administered or with a therapist. It is often combined with postural drainage (gravity-assisted positioning to drain different lung segments), though postural drainage alone is less used today because of Trendelenburg-related gastroesophageal reflux, which is common in CF. A trained CF physiotherapist can design an ACBT program specifically for your lung segment patterns of mucus accumulation.

Aerobic exercise has both direct and indirect airway clearance benefits in CF. During vigorous exercise, increased respiratory rate, tidal volume, and expiratory flow assist in mobilizing secretions, making post-exercise coughing more productive. Over time, regular aerobic exercise helps maintain or improve FEV1 and exercise capacity, reduces anxiety and depression, and improves quality of life. The CF Foundation recommends 150+ minutes per week of moderate-to-vigorous aerobic exercise for adults and ageappropriate amounts for children. Swimming is particularly favored for CF because the prone positioning, breathing patterns, and high respiratory demand all contribute to mucus mobilization. Running, cycling, basketball, and team sports are also excellent. For patients with severe lung disease (FEV1 <40%), supervised cardiac pulmonary exercise testing before starting an intense regimen is advisable. Exercise does not replace ACT — it complements it.

Denufosol tetrasodium (inhaled) was designed to bypass the underlying CFTR defect entirely by activating alternative chloride channels (P2Y2 receptors) in airway epithelial cells, thereby hydrating the mucus layer without correcting CFTR itself. Early Phase 2 results were encouraging. However, two large Phase 3 trials (TIGER-1 and TIGER-2, enrolling hundreds of patients each) failed to demonstrate significant improvement in FEV1 percent predicted at 48 weeks versus placebo. Development was discontinued by Inspire Pharmaceuticals around 2012. The failure highlighted that CFTR-bypass strategies face a ceiling: they can partially compensate but cannot replicate the ion transport architecture that functioning CFTR provides.

The 1990s and 2000s saw multiple clinical trials testing gene delivery vehicles for CFTR — first adenoviral vectors, then liposomal vehicles (lipoplexes). While transient CFTR expression was achievable, the magnitude of correction was too small and too short-lived to produce clinical benefit. Adenoviral vectors triggered immune responses that prevented repeat dosing. Liposomal vectors were better tolerated but still showed insufficient transfection efficiency. Lentiviral vectors in the 2010s showed improved durability in animal models, but human translation remained difficult. Current gene therapy research has shifted to lentiviral and AAV vectors with airway tropism improvements and to base-editing and mRNA approaches, but none has reached clinical approval as of 2026. The years of failed trials established critical lessons about airway biology and immune evasion that are informing the current generation of approaches.

High-dose ibuprofen is unique: it is one of the few therapies proven in randomized controlled trials to slow lung function decline in CF, specifically in children and adolescents aged 5–13. A landmark multi-center CF Foundation trial demonstrated that sustained plasma concentrations of 50–100 mcg/mL reduced the rate of FEV1 decline by approximately 40% over four years. The FDA label supports this use. However, adoption has been very limited for practical reasons:

• The target plasma level requires pharmacokinetic monitoring with regular blood draws — the therapeutic window is narrow (too low = no effect; too high = increased GI bleeding risk)
• Renal and gastrointestinal toxicity risks increase with longer duration and higher doses
• The demonstrated benefit was largely in younger children; evidence in adults is weaker
• The emergence of highly effective CFTR modulators (ivacaftor, elexacaftor/tezacaftor/ivacaftor) has dramatically shifted the clinical landscape — most patients on ETI show FEV1 improvements that make anti-inflammatory adjuncts less urgent

High-dose ibuprofen is still listed in CF Foundation evidence-based guidelines as an option for ages 6–17 not on ETI, but its real-world use has sharply declined. If you or your child is not a candidate for or not responding to CFTR modulators, ask your care team whether it is still worth considering.

N-acetylcysteine (NAC), a thiol-containing compound, was historically one of the few available inhaled mucolytics for CF. It breaks disulfide bonds in mucus glycoproteins, theoretically reducing viscosity. However, NAC is irritating to the airway when inhaled, and controlled trials did not demonstrate meaningful clinical benefit sufficient to support its use as a primary mucolytic. The introduction of dornase alfa (Pulmozyme, approved 1993) — a recombinant human DNase that specifically degrades the extracellular DNA that constitutes a major source of CF mucus viscosity — offered a more targeted and better-tolerated approach. Dornase alfa demonstrated statistically significant FEV1 improvement in Phase 3 trials and has since become standard of care. NAC is no longer recommended as a primary mucolytic in CF per CF Foundation guidelines, though some clinicians use oral NAC as an antioxidant adjunct. The lesson: rheological improvement in CF mucus requires targeting the DNA scaffolding, not just general chemical reduction.

For decades, some CF centers used prophylactic anti-staphylococcal antibiotics (typically oral flucloxacillin) in CF infants and young children, based on the reasoning that early Staphylococcus aureus (MSSA) colonization was harmful and could be prevented. A large European randomized trial (PROPHYLAXIS trial, over 200 infants) showed that while prophylactic flucloxacillin did reduce MSSA colonization rates, it paradoxically increased rates of Pseudomonas aeruginosa colonization. Early Pa colonization carries significantly worse long-term prognosis than MSSA colonization. The CF Foundation now advises against routine prophylactic anti-staphylococcal antibiotics in infants and young children, as the risk of promoting Pa acquisition outweighs the benefit of MSSA suppression. This is a classic example of a treatment that seems intuitively correct but has unintended consequences that make the net effect harmful.